KERX


Keryx Biopharmaceuticals (KERX): Boris Peaker Sees Big Hurdle Ahead for Auryxia’s Commercial Adoption

KERX pulled Auryxia guidance for the year after a rocky third quarter performance; Cowen’s Boris Peaker thumbs down.

Keryx Biopharmaceuticals (KERX) Announces FDA Approval of Auryxia Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis; Shares Tumble

Keryx Biopharmaceuticals (NASDAQ:KERX) announced that the FDA has approved Auryxia for an additional indication. The approval is for the treatment of iron deficiency anemia in …

Keryx Biopharmaceuticals (KERX) Auryxia Has Analyst Boris Peaker Expecting Positive Chances for Approval in Pre-Dialysis Today; Here’s Why

Cowen weighs in on encouraging ANS Phase III data expecting green light for KERX’s ferric citrate tablets.

Biotech Bulletin of the Week: Gilead Sciences, Inc. (GILD), Vertex Pharmaceuticals Incorporated (VRTX), and Keryx Biopharmaceuticals (KERX)

Gilead’s FDA-Approved Drug Still Faces an Uphill Battle in HCV Ring Gilead Sciences, Inc. (NASDAQ:GILD) just scored a green light from the FDA …

Stock Update (NASDAQ:KERX): Keryx Biopharmaceuticals Announces the Largest Medicare Part D Plan Sponsor Added Auryxia to its Medicare Part D Plan Formularies

Keryx Biopharmaceuticals (NASDAQ:KERX) announced that the nation’s largest Medicare Part D plan sponsor has added Auryxia® (ferric citrate) to its Medicare Part D …

Keryx Biopharmaceuticals (KERX): Focusing On Auryxia Growth

Maxim analyst Jason McCarthy is out today with a new research note on shares of Keryx Biopharmaceuticals (NASDAQ:KERX), after the drug maker reported fourth quarter …

Keryx Biopharmaceuticals (KERX) Reports 4Q and Full Year 2016 Results

Keryx Biopharmaceuticals (NASDAQ:KERX) announced its financial results for the fourth quarter and year ended December 31, 2016. The company also reviewed its commercial …

Company Update (NASDAQ:KERX): Keryx Biopharmaceuticals Announces Publication of Auryxia Phase 3 Trial Results in JASN

Keryx Biopharmaceuticals (NASDAQ:KERX) announced the publication of results from its pivotal Phase 3 study evaluating ferric citrate for iron deficiency anemia (IDA) in …

Company Update (NASDAQ:KERX): Keryx Biopharmaceuticals Announces Case Study Data of Auryxia® Presented at ASN’s Kidney Week

Keryx Biopharmaceuticals (NASDAQ:KERX) announced case study data, which showed that Auryxia® (ferric citrate) lowered and maintained serum phosphorus levels in chronic kidney disease …

Company Update (NASDAQ:KERX): Keryx Biopharmaceuticals Announces Presentations of Phase 3 Trial Results of Ferric Citrate for IDA in Non-Dialysis Dependent Chronic Kidney Disease

Keryx Biopharmaceuticals (NASDAQ:KERX) announced presentation of additional data from its pivotal Phase 3 study for iron deficiency anemia (IDA) and non-dialysis dependent chronic …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts